Matthew C. Abernethy

2018

In 2018, Matthew C. Abernethy earned a total compensation of $2.7M as Chief Financial Officer at Neurocrine Biosciences, a 29% decrease compared to previous year.

Compensation breakdown

Bonus$199,500
Salary$420,000
Stock Awards$1,996,506
Other$69,741
Total$2,685,747

Abernethy received $2M in stock awards, accounting for 74% of the total pay in 2018.

Abernethy also received $199.5K in bonus, $420K in salary and $69.7K in other compensation.

Rankings

In 2018, Matthew C. Abernethy's compensation ranked 4,349th out of 14,244 executives tracked by ExecPay. In other words, Abernethy earned more than 69.5% of executives.

ClassificationRankingPercentile
All
4,349
out of 14,244
70th
Division
Manufacturing
1,615
out of 5,765
72nd
Major group
Chemicals And Allied Products
579
out of 2,128
73rd
Industry group
Drugs
483
out of 1,817
73rd
Industry
Biological Products, Except Diagnostic Substances
95
out of 339
72nd

Pay ratio

Matthew C. Abernethy's Pay$2,685,747
Median Employee's Pay$259,000
Pay Ratio

10

to 1

In 2018, the annual total compensation of Matthew C. Abernethy was $2,685,747.

The annual total compensation of the median employee at Neurocrine Biosciences was $259,000.

The ratio of Matthew C. Abernethy's pay to the pay of median employee was therefore 10 to one.

Source: SEC filing on April 17, 2019.

Abernethy's colleagues

We found five more compensation records of executives who worked with Matthew C. Abernethy at Neurocrine Biosciences in 2018.

2018

Kevin Gorman

Neurocrine Biosciences

Chief Executive Officer

2018

Eiry Roberts

Neurocrine Biosciences

Chief Medical Officer

2018

Kyle Gano

Neurocrine Biosciences

Chief Business Development Officer

2018

Eric Benevich

Neurocrine Biosciences

Chief Commercial Officer

2018

Haig Bozigian

Neurocrine Biosciences

Chief Development Officer

News

You may also like